Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Medical Scientist Training Program, Vanderbilt University School of Medicine, 2200 Pierce Ave. 610 Robinson Research Building, Nashville, TN, 37232, USA.
Neurosurg Rev. 2020 Jun;43(3):873-880. doi: 10.1007/s10143-018-1047-9. Epub 2018 Nov 5.
While deep brain stimulation (DBS) treatment is relatively rare in children, it may have a role in dystonia to reduce motor symptoms and disability. Pediatric DBS studies are sparse and limited by small sample size, and thus, outcomes are poorly understood. Thus, we performed a systematic review of the literature including studies of DBS for pediatric (age < 21) dystonia. Patient demographics, disease causes and characteristics, motor scores, and disability scores were recorded at baseline and at last post-operative follow-up. We identified 19 studies reporting DBS outcomes in 76 children with dystonia. Age at surgery was 13.8 ± 3.9 (mean ± SD) years, and 58% of individuals were male. Post-operative follow-up duration was 2.8 ± 2.8 years. Sixty-eight percent of patients had primary dystonia (PD), of whom 56% had a pathological mutation in DYT1 (DYT1+). Across all patients, regardless of dystonia type, 43.8 ± 36% improvement was seen in Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor (-M) scores after DBS, while 43.7 ± 31% improvement was observed in BFMDRS disability (-D) scores. Patients with PD were more likely to experience ≥ 50% improvement (56%) in BFMDRS-M scores compared to patients with secondary causes of dystonia (21%, p = 0.004). DYT1+ patients were more likely to achieve ≥ 50% improvement (65%) in BFMDRS-D than DTY1- individuals (29%, p = 0.02), although there was no difference in BFMDRS-M ≥ 50% improvement rates between DYT1+ (66%) or DYT1- (43%) children (p = 0.11). While DBS is less common in pediatric patients, individuals with severe dystonia may receive worthwhile benefit with neuromodulation treatment.
虽然深部脑刺激(DBS)治疗在儿童中相对较少见,但它可能在治疗肌张力障碍以减轻运动症状和残疾方面发挥作用。儿科 DBS 研究很少且受到样本量小的限制,因此,其结果了解甚少。因此,我们对包括儿童(年龄<21 岁)肌张力障碍 DBS 研究的文献进行了系统回顾。记录患者的人口统计学、疾病病因和特征、运动评分和残疾评分,基线和最后一次术后随访。我们确定了 19 项研究,报告了 76 例肌张力障碍儿童的 DBS 结果。手术年龄为 13.8±3.9(平均值±标准差)岁,58%的个体为男性。术后随访时间为 2.8±2.8 年。68%的患者患有原发性肌张力障碍(PD),其中 56%的患者在 DYT1 中存在病理性突变(DYT1+)。在所有患者中,无论肌张力障碍类型如何,DBS 后 Burke-Fahn-Marsden 肌张力障碍评定量表(BFMDRS)运动(-M)评分的改善率为 43.8±36%,而 BFMDRS 残疾(-D)评分的改善率为 43.7±31%。与继发性肌张力障碍患者(21%,p=0.004)相比,PD 患者 BFMDRS-M 评分≥50%改善的可能性更高(56%)。DYT1+患者在 BFMDRS-D 中达到≥50%改善的可能性(65%)高于 DTY1-个体(29%,p=0.02),但 DYT1+(66%)或 DYT1-(43%)儿童的 BFMDRS-M≥50%改善率之间没有差异(p=0.11)。虽然 DBS 在儿科患者中较少见,但严重肌张力障碍患者可能会从神经调节治疗中获得有价值的益处。